Integrated genomic characterisation of endometrial carcinoma (The Cancer Genome Atlas)
Sequencing of 373 endometrial cancers revealed four molecular groups, POLE ultramutated, microsatellite unstable, copy-number low and copy-number high, that cut across the traditional endometrioid and serous types and predict outcome.
Overview
Integrated genomic, transcriptomic and proteomic analysis of 373 endometrial carcinomas by The Cancer Genome Atlas defining four groups: POLE ultramutated (with excellent outcome), microsatellite instability hypermutated, copy-number low (endometrioid) and copy-number high (serous-like, TP53-mutated, worst outcome); about a quarter of high-grade endometrioid tumours resembled serous carcinoma molecularly.
- Four molecular subgroups with distinct progression-free survival.
- 25 percent of high-grade endometrioid tumours had serous-like copy-number-high profiles.
This is the origin of the molecular classification now used for every endometrial cancer, translated into a practical test by ProMisE.
- Research-grade sequencing; clinical surrogates were needed for routine use.
Similar pages
not linked directly; found by shared links- Key paperMolecular classification of the PORTEC-3 trial: prognosis and benefit from adjuvant chemotherapy by molecular group
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma.
- Key paperConfirmation of ProMisE: a genomics-based clinical classifier for endometrial cancer
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma.
- TermHysterectomy
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma.
- TermEndometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma.
- TrialPORTEC-3
Shares POLE-ultramutated endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma.